FUNDAMENTALS · Fundamentals · TW Healthcare

BIONET (1784) Fundamentals 2026 — P/E 62.7x, Revenue Analysis | SniperIQ

BIONET (1784) is a TW-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of NT

.1B, trading at NT$60.80 on the TWO. This SniperIQ fundamentals page covers BIONET's valuation (P/E 62.7x, P/B 0.0x), profitability (net margin 3.0%), revenue (NT
.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT
.1B
P/E (TTM)62.7x
Net Margin3.0%
Revenue (FY25)NT
.2B

Full research coverage

Frequently Asked Questions

What is BIONET's market cap?

BIONET (1784) has a market capitalization of approximately NT

.1B, trading at NT$60.80 on the TWO. Market cap moves with the live share price.

What is BIONET's P/E ratio?

BIONET's trailing twelve-month P/E ratio is 62.7x, with a price-to-book (P/B) of 0.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is BIONET?

BIONET runs a net profit margin of 3.0%, a gross margin of 55.2%, and an operating margin of -1.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does BIONET generate?

BIONET reported revenue of NT

.2B for fiscal year 2025, with net income of NT$51M and earnings per share (EPS) of 1.02. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does BIONET pay a dividend?

BIONET offers a trailing dividend yield of about 2.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is BIONET financially healthy?

BIONET carries a debt-to-equity ratio of 0.11x and a current ratio of 4.23x, with a market beta of 0.47. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is BIONET a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For BIONET (1784) the key facts are: market cap NT

.1B, P/E 62.7x, revenue NT
.2B, 52-week range 60-118. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track BIONET's full fundamentals live

Get BIONET's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.